PHARMACY

Reports: N.Y. Gov. Cuomo signs controversial mail-order pharmacy bill

BY Alaric DeArment

NEW YORK — New York state Gov. Andrew Cuomo has signed into law a bill that would forbid health insurers from requiring plan members to order prescription drugs from mail-order pharmacies, according to published reports. 

The governor signed the bill, AB 5502-B, sponsored by Democratic Rep. Carl Heastie from the Bronx, after both houses agreed to amend it to require retail pharmacies to agree in advance to accept reimbursement rates and terms and conditions identical to those for mail-order pharmacies. The bill would also prohibit insurers from exempting patients who buy through mail-order from co-pays while charging patients who obtain their drugs through some other channel, such as a retail pharmacy.

Supporters of the bill have said it will give consumers more freedom in determining how they get their prescription drugs and have also pointed what they consider to be risks of mail-order pharmacy, such as temperature-sensitive drugs left on patients’ doorsteps in weather that could damage them. In addition, supporters say, the ability to pick drugs up at a retail pharmacy allows patients to interact face to face with pharmacists and take advantage of services such as medication therapy management.

The amendments drew a response from the pharmacy benefit manager lobby, which has opposed the bill. The Federal Trade Commission has expressed reservations about it as well.

"Employers, taxpayers and consumers appreciate Gov. Cuomo’s admonition to the legislature to improve this costly, anti-consumer bill," Pharmaceutical Care Management Association president and CEO Mark Merritt said. "In this economy, employers need every cost-saving tool they can get, and mail-service pharmacy is at the top of the list."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

N.LEGAKIS says:
Dec-13-2011 05:59 pm

It's about time. Can't wait to welcome so many customers back that were FORCED to leave us. Nothing beats personalized extraordinarily ordinary sevice and care with a name and a smile. Thank you Gov. and God Bless America.

TRENDING STORIES

PHARMACY

Report: Authorized generic versions of Lipitor capture 14.6% of script volume

BY Alaric DeArment

NEW YORK — Though they’ve been on the market for less than a month, the generic and authorized generic versions of Pfizer’s cholesterol-lowering drug Lipitor have captured more than one-tenth of prescriptions, according to published reports.

Citing an analysis of data from IMS Health by J.P. Morgan, The Wall Street Journal reported that Ranbaxy’s generic atorvastatin calcium tablets and Watson Pharmaceuticals’ authorized generic have claimed about 14.6% of prescription volume since their launch on Nov. 30.

Ranbaxy and Watson respectively launched their generic and authorized generic versions of Lipitor the day Pfizer lost its patent protection for the drug, which IMS estimated to have sales of $7.8 billion during the latest moving-annual period. An authorized generic is a branded drug launched under its generic name at a reduced price, usually under a contract between the original branded drug’s manufacturer and a third-party company.

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

J.WISHNIA says:
Dec-14-2011 11:08 pm

I am a retired pharmacist. I went to get my Lipitor refilled and found out the Brand Name Lipitor and the new generic version was to cost me the exact same price. This was through Community Rx Part D, I am in the doughnut hole, so I just decided to wait until January and get the Rx filled....... Jacob Wishnia R.Ph.

TRENDING STORIES

PHARMACY

Amneal makes new executive appointments

BY Alaric DeArment

BRIDGEWATER, N.J. — Generic drug maker Amneal Pharmaceuticals has added four new executives, the company said.

Joseph Todisco has been appointed SVP global corporate strategy and business development. Previously serving as VP business development for Ranbaxy, Todisco will be responsible for the growth of Amneal’s U.S. generics business and development of partnerships, mergers and acquisitions.

Narasimhan Mani has been appointed director of global business development and portfolio, and will head the identification and execution of international opportunities and alliances, research and development product management and selection, and corporate portfolio management. Before working for Amneal, Mani was business development manager for Johnson & Johnson.

Pranav Mehta has been appointed global director of purchasing, overseeing research and development procurement, commercial active pharmaceutical ingredients and packaging. Mehta previously worked for JPMorgan Chase & Co.

Hanumantha Rao has been appointed director of business development and will seek alliances in Europe, Asia, Africa and the Middle East. Before working for Amneal, Rao was assistant director of strategic sourcing and business development for North America and Europe at Dr. Reddy’s Labs.

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES